The phase 3b trial, led by Weill Cornell Medicine and NewYork-Presbyterian, enrolled patients from the SURMOUNT-5 study and represents the first head-to-head data on longer-term weight maintenance using an oral GLP-1 following injectable therapy
The US Food and Drug Administration (FDA) has approved the oral formulation of the GLP-1 weight-loss drug Wegovy, making it the first oral GLP-1 therapy cleared for obesity treatment ahead of rival Eli Lillys orforglipron, which is still under FDA review

Key Ingredients Potent 0.2% Copper Peptide: one of the biggest powerhouse peptides impacting skin texture and strength, prevents and reverses the appearance of fine lines and wrinkles 12 additional high-performing peptides: penetrate deep into skin to boost firming and smoothing benefits 4 powerhouse amino acids: essential building blocks of collagen and elastin, amplify peptide results and help skin retain moisture Hyaluronic Acid and Squalane: deeply hydrate and maximize skins elasticity Time-tested Korean Root Extracts: chicory root and shiitake mushroom calm skin and visibly protect against environmental stressors Research Results 96% noticed a visible improvement in skin firmness* *Results from a third party consumer study Item 2612448 Apply to skin after cleansing and toning
Cancer Res (2014) 74:357990
Pediatric Use Intake in pediatric patients should be in the amount recommended by the Food and Nutrition Board, National Academy of Science-National Research Council